Polyarticular Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Polyarticular Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients [Phase 4]
Phase 4 clinical trial comparing leflunomide plus methotrexate versus methotrexate alone in refractory polyarticular juvenile idiopathic art…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.
-
FDA approval · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.
-
FDA label_change · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) submitted by Genentech, Inc., related to changes to the product labeling.
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases [Phase 1]
Phase 1 clinical trial evaluating a BCMA/CD70-targeted CAR-T therapy for refractory pediatric rheumatic diseases is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
This completed observational study evaluated changes in disease activity and adverse events in Chinese pediatric participants with polyartic…
-
FDA approval · 2025-03-13FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC.
-
FDA approval · 2024-03-05FDA Approved: TYENNE — Original Application (Fresenius Kabi USA, LLC)
FDA approved TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC under an Original Application.
-
FDA approval · 2021-10-22FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) from Genentech, expanding its labeling and/or indications. The action conf…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Start Time Optimization of Biologics in Polyarticular JIA
Clinical trial update on start time optimization of biologics in polyarticular juvenile idiopathic arthritis has completed with results post…
-
CLINICAL_TRIALS trial_result · 2020-11-18Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy [Phase 3]
Phase 3 study evaluating intravenous golimumab in pediatric patients with active polyarticular juvenile idiopathic arthritis despite methotr…
-
FDA approval · 2019-06-11FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) filed by Genentech, Inc., resulting in an approved update to the product's…
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Surveillance of Humira in Korean JIA Patients
A post-marketing safety surveillance study of Humira (adalimumab) in Korean patients with polyarticular juvenile idiopathic arthritis has co…
-
FDA approval · 2017-05-22FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. The supplementary filing status is AP (approv…
-
CLINICAL_TRIALS trial_result · 2016-03-24Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) [Phase 3]
Phase 3 trial evaluating pharmacokinetics, efficacy, and safety of subcutaneous abatacept in children with active polyarticular juvenile idi…
-
CLINICAL_TRIALS trial_result · 2014-04-16Clinical Trial Update: Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis [Phase 2]
Phase 2 dose-finding trial of givinostat for Polyarticular Juvenile Idiopathic Arthritis was terminated; results were posted in 2014.
-
FDA approval · 2012-08-13FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) submitted by Genentech, broadening its labeling.
-
CLINICAL_TRIALS research · 2012-03-22Clinical Trial Update: Ultrasonography in Juvenile Idiopathic Arthritis
A completed clinical trial update examining the use of ultrasonography in juvenile idiopathic arthritis.
-
CLINICAL_TRIALS trial_result · 2009-12-23Clinical Trial Update: Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) [Phase 3]
A Phase 3 long-term treatment study of MRA for polyarticular juvenile idiopathic arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2008-07-30Clinical Trial Update: Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) [Phase 3]
Phase 3 clinical trial evaluating MRA for polyarticular juvenile idiopathic arthritis has completed.